CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 247 enrolled
Drug / intervention
lithium and Venlafaxine +1 moredrug
Likely dose
lithium and Venlafaxine 225 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01028508
NCT01028508Phase 4Completed
CompareCT.gov

Prolonging Remission in Depressed Elderly (PRIDE)

Icahn School of Medicine at Mount Sinai·interventional·Posted Dec 9, 2009·Updated Apr 11, 2017

In Brief

A Phase 4 clinical trial evaluating lithium and Venlafaxine and ECT for Depression. Completed, enrolled 247 participants across 10 sites.

Detailed Summary

This study will determine whether medications alone or medications and electroconvulsive therapy (ECT) work best to prevent depressive relapse and to improve quality of life for older people with severe mood disorders.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepression
CountriesUnited States
CollaboratorsNational Institute of Mental Health (NIMH)

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 9, 2009
Enrollment StartJan 1, 2010
Primary CompletionSep 1, 2015
Study CompletionMar 1, 2016
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 16.6 years ago

Interventions

lithium and Venlafaxinedrug

Drug: VLF Target dose 225 mg/day Drug: Li Target serum concentration 0.7 mEq/l

ECTprocedure

Procedure: ECT RUL ultra brief pulse ECT, 4 treatments in one month and then treatment on an as-needed basis for 5 months Drug: VLF Target dose 225 mg/day Drug: Li Target serum concentration 0.7 mEq/l